Share Email Print

Proceedings Paper

In vivo monitoring of photosensitizer fluorescence during photodynamic therapy
Author(s): Mark R. Stringer; Dominic J. Robinson; Emma J. Hudson; Michael A. Smith
Format Member Price Non-Member Price
PDF $17.00 $21.00

Paper Abstract

A method is presented of monitoring the low level fluorescence emitted by the photosensitizing agent protoporphyrin IX during superficial photodynamic therapy of skin carcinomas, using 630 nm illumination. A fiber optic probe samples the light field which is filtered and recorded by an optical spectrum analyzer. The technique is minimally invasive and can proceed concurrently with light dosimetry measurements. This paper presents in vitro data that define the sensitivity and selectivity of the technique, along with preliminary in vivo measurements. These indicate that it is the rate of phototransformation of the photosensitizer, rather than the total light dose, that determines the optimum treatment duration. Clinically effective treatment therefore depends upon achieving a threshold concentration of drug throughout the volume of the lesion. In this way the effect of phototransformation does not inactivate the drug before complete tumor necrosis occurs.

Paper Details

Date Published: 1 March 1995
PDF: 5 pages
Proc. SPIE 2371, 5th International Photodynamic Association Biennial Meeting, (1 March 1995); doi: 10.1117/12.203433
Show Author Affiliations
Mark R. Stringer, Univ. of Leeds (United Kingdom)
Dominic J. Robinson, Univ. of Leeds (United Kingdom)
Emma J. Hudson, Univ. of Leeds (United Kingdom)
Michael A. Smith, Univ. of Leeds (United Kingdom)

Published in SPIE Proceedings Vol. 2371:
5th International Photodynamic Association Biennial Meeting
Denis A. Cortese, Editor(s)

© SPIE. Terms of Use
Back to Top